http://biz.yahoo.com/ic/news/516.htmlThe latest news on the Diagnostic Substances industry from Yahoo! Financeen-usMon, 23 Nov 2009 22:23:00 Etc/GMThttp://us.news2.yimg.com/us.yimg.com/p/fi/pr/40197.gifhttp://finance.yahoo.com14417http://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/prnews/091123/cl16332.html?.v=1Immucor, Inc. , a global leader in providing automated instrument-reagent systems to the blood transfusion industry, today announced that access to its presentation at the Piper Jaffray 21st Annual Health Care Conference in New York, NY will be available via a live, simultaneous webcast.yahoo_finance/3579121397Mon, 23 Nov 2009 22:23:00 Etc/GMThttp://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/ap/091123/us_raptor_pharmaceutical_study.html?.v=2Raptor Pharmaceutical Corp. said Monday its developing treatment for the genetic disorder nephropathic cystinosis met key goals in a midstage study.yahoo_finance/2159416835Mon, 23 Nov 2009 16:05:21 Etc/GMThttp://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/pz/091123/178971.html?.v=1HASBROUCK HEIGHTS, N.J. -- Nymox Pharmaceutical Corporation announced today the release of positive new clinical trial data from responder analysis of the Company's pooled multi-center U.S.yahoo_finance/3371991223Mon, 23 Nov 2009 15:47:56 Etc/GMThttp://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/prnews/091123/de15833.html?.v=1yahoo_finance/3623857346Mon, 23 Nov 2009 14:15:00 Etc/GMThttp://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/prnews/091123/ny15728.html?.v=1Raptor Pharmaceutical Corp. , today announced results from a Phase 2b clinical trial of its proprietary delayed-release cysteamine bitartrate in patients with nephropathic cystinosis .yahoo_finance/1099405875Mon, 23 Nov 2009 11:30:00 Etc/GMThttp://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/prnews/091123/ny15729.html?.v=1Raptor Pharmaceutical Corp. today announced the presentation of clinical trial data on NGX426, the Company's orally administered, non-opioid, AMPA/kainate receptor antagonist, at the 12th International Conference on the Mechanisms and Treatment of Neuropathic Pain, held on November 20-21 in San Francisco.yahoo_finance/2355010750Mon, 23 Nov 2009 11:30:00 Etc/GMThttp://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/pz/091118/178699.html?.v=1yahoo_finance/2061966772Wed, 18 Nov 2009 16:21:15 Etc/GMThttp://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/bw/091118/20091118005622.html?.v=1LEXINGTON, Mass.----Synta Pharmaceuticals Corp. , a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that preclinical data presented at the AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics shows that STA-9090, a novel, synthetic inhibitor of heat shock protein 90 , demonstrated strong activity in multiple tumor models, including lung cancer, gastrointestinal stromal tumors , prostate cancer, colon cancer, breast cancer, gastric cancer, pancreatic cancer, colon cancer, melanoma, acute myeloid leukemia, chronic myeloid leukemia, acute lymphoblastic leukemia, B-cell lymphoma, and multiple myeloma.yahoo_finance/2819510996Wed, 18 Nov 2009 13:01:00 Etc/GMThttp://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/bw/091118/20091118005621.html?.v=1LEXINGTON, Mass.----Synta Pharmaceuticals Corp. , a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today presented new data on the mechanism of action of elesclomol, a first-in-class oxidative stress inducer, at the AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics in Boston, Mass.yahoo_finance/2426454695Wed, 18 Nov 2009 13:00:00 Etc/GMThttp://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/pz/091117/178528.html?.v=1yahoo_finance/2484718230Tue, 17 Nov 2009 21:05:00 Etc/GMThttp://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/zacks/091117/27373.html?.v=1Quidel Enters Oversold Territoryyahoo_finance/273423039Tue, 17 Nov 2009 15:47:53 Etc/GMThttp://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/iw/091117/0559680.html?.v=1yahoo_finance/3409329178Tue, 17 Nov 2009 13:30:00 Etc/GMThttp://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/pz/091117/178524.html?.v=1yahoo_finance/565121866Tue, 17 Nov 2009 13:00:00 Etc/GMThttp://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/bw/091116/20091116006663.html?.v=1LOS ANGELES----Response Genetics Inc. , a company focused on the development and sale of molecular diagnostic tests for cancer, today announced its consolidated financial results for the three and nine months ended September 30, 2009.yahoo_finance/3509199632Mon, 16 Nov 2009 21:05:00 Etc/GMThttp://us.rd.yahoo.com/finance/external/trsa/rss/SIG=13e7nug99/*http%3A//seekingalpha.com/article/173653-palatin-technologies-f1q10-qtr-end-9-30-09-earnings-call-transcript?source=yahooyahoo_finance/703049603Mon, 16 Nov 2009 20:50:22 Etc/GMThttp://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/pz/091116/178480.html?.v=1SOUTH EASTON, Mass. -- Pressure BioSciences, Inc. today announced that total revenue for the third quarter of 2009 was $317,427 compared to $265,662 for the comparable period in 2008, a 19% increase.yahoo_finance/2728478618Mon, 16 Nov 2009 15:55:00 Etc/GMThttp://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/ap/091116/us_neogen_stock_split.html?.v=1Neogen Corp., which makes test kits for food and animal safety, said Monday its board approved a 3-for-2 stock split. Shareholders of record on Nov. 30 will receive one additional share of stock for each two shares held.yahoo_finance/3779169804Mon, 16 Nov 2009 15:13:54 Etc/GMThttp://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/pz/091116/178475.html?.v=1yahoo_finance/41526034Mon, 16 Nov 2009 14:30:00 Etc/GMThttp://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/prnews/091116/de11634.html?.v=1yahoo_finance/678491459Mon, 16 Nov 2009 14:15:00 Etc/GMThttp://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/bw/091116/20091116005589.html?.v=1NEW YORK & PETACH TIKVAH, Israel----BrainStorm Cell Therapeutics Inc. , a leading developer of adult stem cell technologies and therapeutics, is pleased to announce that the company’s therapeutic approach for treating neurodegenerative diseases, particularly ALS and Parkinson’s disease, was found to have a positive effect in a mouse model of multiple sclerosis .yahoo_finance/93387458Mon, 16 Nov 2009 13:00:00 Etc/GMT